Kunz R , et al.. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148:30–48.

• PubMed
Kunz R , . Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148:30–48.)| false
• Search Google Scholar
• Export Citation

Kalaitzidis RG , Bakris GL . Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Curr Opin Nephrol Hypertens 2009; 18:386–391.

• PubMed
Kalaitzidis RG , Bakris GL . Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Curr Opin Nephrol Hypertens 2009; 18:386–391.)| false
• Search Google Scholar
• Export Citation

Kalaitzidis RG , Bakris GL . Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol 2010; 8:604–611.

• PubMed
Kalaitzidis RG , Bakris GL . Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol 2010; 8:604–611.)| false
• Search Google Scholar
• Export Citation

Lea J , et al.. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165:947–953.

• PubMed
Lea J , . The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165:947–953.)| false
• Search Google Scholar
• Export Citation

Wheeler DC , Becker GJ . Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int 2013; 83:377–383.

• PubMed
Wheeler DC , Becker GJ . Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int 2013; 83:377–383.)| false
• Search Google Scholar
• Export Citation

Mauer M , et al.. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361:40–51.

• PubMed
Mauer M , . Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361:40–51.)| false
• Search Google Scholar
• Export Citation

Glassock RJ . Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010; 31:462–465.

• PubMed
Glassock RJ . Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010; 31:462–465.)| false
• Search Google Scholar
• Export Citation

Bakris G . Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol 2010; 105:21A–29A.

• PubMed
Bakris G . Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol 2010; 105:21A–29A.)| false
• Search Google Scholar
• Export Citation

Verdecchia P , et al.. Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol 2011; 4:151–161.

• PubMed
Verdecchia P , . Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol 2011; 4:151–161.)| false
• Search Google Scholar
• Export Citation

Bakris GL , et al.. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich ) 2013; 15:92–100.

• PubMed
Bakris GL , . Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich ) 2013; 15:92–100.)| false
• Search Google Scholar
• Export Citation

Lazich I , Bakris GL . Endothelin antagonism in patients with resistant hypertension and hypertension nephropathy. Contrib Nephrol 2011; 172:223–234.

• PubMed
Lazich I , Bakris GL . Endothelin antagonism in patients with resistant hypertension and hypertension nephropathy. Contrib Nephrol 2011; 172:223–234.)| false
• Search Google Scholar
• Export Citation

Bakris GL , et al.. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 2010; 56:824–830.

• PubMed
Bakris GL , . Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 2010; 56:824–830.)| false
• Search Google Scholar
• Export Citation

Andress DL , et al.. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci 2012; 91:739–742.

• PubMed
Andress DL , . Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci 2012; 91:739–742.)| false
• Search Google Scholar
• Export Citation

Kohan DE , Pollock DM . Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br J Clin Pharmacol 2013; 76:573–579.

• PubMed
Kohan DE , Pollock DM . Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br J Clin Pharmacol 2013; 76:573–579.)| false
• Search Google Scholar
• Export Citation